Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/CD20 Dual CAR-T Cells in R/R B-NHL
NCT04697290Phase 1Suspended
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- Mar 2022
- Primary completion
- Mar 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19/CD20 dual CAR-T in B-cell non-Hodgkin lymphoma, sponsored by Beijing Tsinghua Changgung Hospital. Primary endpoints: Percentage of adverse events at 6 months and Objective remission rate at 6 months. Started Mar 2022; status: suspended.
02
Drugs
CD19/CD20 dual CAR-T
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04697290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04697290.